FOXM1: An emerging master regulator of DNA damage response and genotoxic agent resistance

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1839, Issue 11, 2014, Pages 1316-1322

  Zona, Stefania ^a   Bella, Laura ^a   Burton, Matthew J ^a   Nestal de Moraes, Gabriela ^a   Lam, Eric W F ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; DNA damage; Drug resistance; FOXM1; Transcriptional targets

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; EPIRUBICIN; ETOPOSIDE; PLATINUM DERIVATIVE; TEMOZOLOMIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN;

ANGIOGENESIS; APOPTOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CHROMATIN STRUCTURE; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DNA END JOINING REPAIR; DNA METHYLATION; DNA REPAIR; DNA STRAND BREAKAGE; EXCISION REPAIR; GENE EXPRESSION; GENETIC CODE; GENETIC DAMAGE; GENOTOXICITY; HOMOLOGOUS RECOMBINATION; HUMAN; IONIZING RADIATION; METASTASIS; MISMATCH REPAIR; RADIOSENSITIVITY; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION INITIATION; TREATMENT FAILURE; TUMOR INVASION; ULTRAVIOLET RADIATION; ANIMAL; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS;

EID: 84908583907     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2014.09.016     Document Type: Review

References (85)

1. Koo C.Y., Muir K.W., Lam E.W. FOXM1: from cancer initiation to progression and treatment. Biochim. Biophys. Acta 2012, 1819:28-37.
2. Lam E.W., Brosens J.J., Gomes A.R., Koo C.Y. Forkhead box proteins: tuning forks for transcriptional harmony, nature reviews. Cancer 2013, 13:482-495.
3. Lam A.K., Ngan A.W., Leung M.H., Kwok D.C., Liu V.W., Chan D.W., Leung W.Y., Yao K.M. FOXM1b, which is present at elevated levels in cancer cells, has a greater transforming potential than FOXM1c. Front. oncol. 2013, 3:11.
4. Bella L., Zona S., Nestal de Moraes G., Lam E.W. FOXM1: a key oncofoetal transcription factor in health and disease. Semin. Cancer Biol Jul 25 2014, Epub ahead of print). 10.1016/j.semcancer.2014.07.008 (pii: S1044-579X(14)00096-0.
5. Kalinina O.A., Kalinin S.A., Polack E.W., Mikaelian I., Panda S., Costa R.H., Adami G.R. Sustained hepatic expression of FoxM1B in transgenic mice has minimal effects on hepatocellular carcinoma development but increases cell proliferation rates in preneoplastic and early neoplastic lesions. Oncogene 2003, 22:6266-6276.
6. Kalin T.V., Wang I.C., Ackerson T.J., Major M.L., Detrisac C.J., Kalinichenko V.V., Lyubimov A., Costa R.H. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 2006, 66:1712-1720.
7. Kim I.M., Ackerson T., Ramakrishna S., Tretiakova M., Wang I.C., Kalin T.V., Major M.L., Gusarova G.A., Yoder H.M., Costa R.H., Kalinichenko V.V. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res. 2006, 66:2153-2161.
8. Liu M., Dai B., Kang S.H., Ban K., Huang F.J., Lang F.F., Aldape K.D., Xie T.X., Pelloski C.E., Xie K., Sawaya R., Huang S. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res. 2006, 66:3593-3602.
9. Madureira P.A., Varshochi R., Constantinidou D., Francis R.E., Coombes R.C., Yao K.M., Lam E.W. The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J. Biol. Chem. 2006, 281:25167-25176.
10. Wang Z., Banerjee S., Kong D., Li Y., Sarkar F.H. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 2007, 67:8293-8300.
11. Yoshida Y., Wang I.C., Yoder H.M., Davidson N.O., Costa R.H. The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology 2007, 132:1420-1431.
12. Teh M.T., Wong S.T., Neill G.W., Ghali L.R., Philpott M.P., Quinn A.G. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res. 2002, 62:4773-4780.
13. Gemenetzidis E., Bose A., Riaz A.M., Chaplin T., Young B.D., Ali M., Sugden D., Thurlow J.K., Cheong S.C., Teo S.H., Wan H., Waseem A., Parkinson E.K., Fortune F., Teh M.T. FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One 2009, 4:e4849.
14. Teh M.T., Gemenetzidis E., Chaplin T., Young B.D., Philpott M.P. Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes. Mol. Cancer 2010, 9:45.
15. Janus J.R., Laborde R.R., Greenberg A.J., Wang V.W., Wei W., Trier A., Olsen S.M., Moore E.J., Olsen K.D., Smith D.I. Linking expression of FOXM1, CEP55 and HELLS to tumorigenesis in oropharyngeal squamous cell carcinoma. Laryngoscope 2011, 121:2598-2603.
16. Huynh K.M., Soh J.W., Dash R., Sarkar D., Fisher P.B., Kang D. FOXM1 expression mediates growth suppression during terminal differentiation of HO-1 human metastatic melanoma cells. J. Cell. Physiol. 2011, 226:194-204.
17. Nakamura S., Hirano I., Okinaka K., Takemura T., Yokota D., Ono T., Shigeno K., Shibata K., Fujisawa S., Ohnishi K. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. Carcinogenesis 2010, 31:2012-2021.
18. Pilarsky C., Wenzig M., Specht T., Saeger H.D., Grutzmann R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 2004, 6:744-750.
19. Uddin S., Hussain A.R., Ahmed M., Siddiqui K., Al-Dayel F., Bavi P., Al-Kuraya K.S. Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma. Haematologica 2012, 97:1092-1100.
20. Wang I.C., Chen Y.J., Hughes D.E., Ackerson T., Major M.L., Kalinichenko V.V., Costa R.H., Raychaudhuri P., Tyner A.L., Lau L.F. FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness. J. Biol. Chem. 2008, 283:20770-20778.
21. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
22. von Zglinicki T., Saretzki G., Ladhoff J., d'Adda di Fagagna F., Jackson S.P. Human cell senescence as a DNA damage response. Mech. Ageing Dev. 2005, 126:111-117.
23. Martin M., Villar A., Sole-Calvo A., Gonzalez R., Massuti B., Lizon J., Camps C., Carrato A., Casado A., Candel M.T., Albanell J., Aranda J., Munarriz B., Campbell J., Diaz-Rubio E. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann. Oncol. 2003, 14:833-842.
24. E.B.C.T.C.G.(EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
25. Alvarez R.H. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res. 2010, 12(Suppl. 2):S1.
26. Alvarez R.H., Valero V., Hortobagyi G.N. Emerging targeted therapies for breast cancer. J. Clin. Oncol. 2010, 28:3366-3379.
27. Palmieri C., Krell J., James C.R., Harper-Wynne C., Misra V., Cleator S., Miles D. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat. Rev. Clin. Oncol. 2010, 7:561-574.
28. Begg A.C., Stewart F.A., Vens C. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer 2011, 11:239-253.
29. Colak S., Medema J.P. Cancer stem cells; important players in tumor therapy resistance. FEBS J Aug 27 2014, (Epub ahead of print). 10.1111/febs.13023.
30. Myatt S.S., Lam E.W. The emerging roles of forkhead box (Fox) proteins in cancer. Nat. Rev. Cancer 2007, 7:847-859.
31. Myatt S.S., Lam E.W. Targeting FOXM1, nature reviews. Cancer 2008, 8:242.
32. Tan Y., Raychaudhuri P., Costa R.H. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol. Cell. Biol. 2007, 27:1007-1016.
33. Zhang N., Wu X., Yang L., Xiao F., Zhang H., Zhou A., Huang Z., Huang S. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin. Cancer Res. 2012, 18:5961-5971.
34. Monteiro L.J., Khongkow P., Kongsema M., Morris J.R., Man C., Weekes D., Koo C.Y., Gomes A.R., Pinto P.H., Varghese V., Kenny L.M., Charles Coombes R., Freire R., Medema R.H., Lam E.W. The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. Oncogene 2013, 32:4634-4645.
35. Kwok J.M., Peck B., Monteiro L.J., Schwenen H.D., Millour J., Coombes R.C., Myatt S.S., Lam E.W. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol. Cancer Res. 2010, 8:24-34.
36. Millour J., de Olano N., Horimoto Y., Monteiro L.J., Langer J.K., Aligue R., Hajji N., Lam E.W. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol. Cancer Ther. 2011, 10:1046-1058.
37. Helleday T., Lo J., van Gent D.C., Engelward B.P. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA repair 2007, 6:923-935.
38. McVey M., Lee S.E. MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. Trends Genet. 2008, 24:529-538.
39. Scharer O.D. Nucleotide excision repair in eukaryotes. Cold Spring Harbor Perspect. Biol. 2013, 5:a012609.
40. Rechkunova N.I., Lavrik O.I. Nucleotide excision repair in higher eukaryotes: mechanism of primary damage recognition in global genome repair. Subcell. Biochem. 2010, 50:251-277.
41. Zhou J., Wang Y., Wang Y., Yin X., He Y., Chen L., Wang W., Liu T., Di W. FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer. PLoS One 2014, 9:e96989.
42. Valle L., Hernandez-Illan E., Bellido F., Aiza G., Castillejo A., Castillejo M.I., Navarro M., Segui N., Vargas G., Guarinos C., Juarez M., Sanjuan X., Iglesias S., Alenda C., Egoavil C., Segura A., Juan M.J., Rodriguez-Soler M., Brunet J., Gonzalez S., Jover R., Lazaro C., Capella G., Pineda M., Soto J.L., Blanco I. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum. Mol. Genet 2014, 23(13):3506-3512.
43. Caldecott K.W. DNA single-strand break repair. Exp. Cell Res Aug 28 2014, Epub ahead of print). 10.1016/j.yexcr.2014.08.027 (pii: S0014-4827(14)00365-6.
44. Marteijn J.A., Lans H., Vermeulen W., Hoeijmakers J.H. Understanding nucleotide excision repair and its roles in cancer and ageing, nature reviews. Mol. Cell Biol. 2014, 15:465-481.
45. Kim H., D'Andrea A.D. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 2012, 26:1393-1408.
46. Bak S.T., Sakellariou D., Pena-Diaz J. The dual nature of mismatch repair as antimutator and mutator: for better or for worse. Front. Genet. 2014, 5:287.
47. San Filippo J., Sung P., Klein H. Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 2008, 77:229-257.
48. Khongkow P., Karunarathna U., Khongkow M., Gong C., Gomes A.R., Yague E., Monteiro L.J., Kongsema M., Zona S., Man E.P., Tsang J.W., Coombes R.C., Wu K.J., Khoo U.S., Medema R.H., Freire R., Lam E.W. FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. Oncogene 2014, 33:4144-4155.
49. So S., Davis A.J., Chen D.J. Autophosphorylation at serine 1981 stabilizes ATM at DNA damage sites. J. Cell Biol. 2009, 187:977-990.
50. Riches L.C., Lynch A.M., Gooderham N.J. Early events in the mammalian response to DNA double-strand breaks. Mutagenesis 2008, 23:331-339.
51. Kitagawa R., Bakkenist C.J., McKinnon P.J., Kastan M.B. Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. Genes Dev. 2004, 18:1423-1438.
52. Lee J.H., Paull T.T. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005, 308:551-554.
53. Matsuoka S., Huang M., Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998, 282:1893-1897.
54. N.Cancer Genome Atlas Research Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
55. Tan Y., Chen Y., Yu L., Zhu H., Meng X., Huang X., Meng L., Ding M., Wang Z., Shan L. Two-fold elevation of expression of FoxM1 transcription factor in mouse embryonic fibroblasts enhances cell cycle checkpoint activity by stimulating p21 and Chk1 transcription. Cell Prolif. 2010, 43:494-504.
56. Hiom K. FANCJ: solving problems in DNA replication. DNA repair 2010, 9:250-256.
57. Cantor S.B., Guillemette S. Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1. Future Oncol. 2011, 7:253-261.
58. Ma L., Wang H., Yao H., Zhu L., Liu W., Zhou Z. Bmi1 expression in oral lichen planus and the risk of progression to oral squamous cell carcinoma. Ann. Diagn. Pathol. 2013, 17:327-330.
59. Mori R., Yoshida K., Tanahashi T., Yawata K., Kato J., Okumura N., Tsutani Y., Okada M., Oue N., Yasui W. Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells. Gastric cancer 2013, 16:345-354.
60. Peng M., Litman R., Xie J., Sharma S., Brosh R.M., Cantor S.B. The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells. EMBO J. 2007, 26:3238-3249.
61. Xie J., Litman R., Wang S., Peng M., Guillemette S., Rooney T., Cantor S.B. Targeting the FANCJ-BRCA1 interaction promotes a switch from recombination to poleta-dependent bypass. Oncogene 2010, 29:2499-2508.
62. Wang I.C., Chen Y.J., Hughes D., Petrovic V., Major M.L., Park H.J., Tan Y., Ackerson T., Costa R.H. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell. Biol. 2005, 25:10875-10894.
63. Wu J., Zhang X., Zhang L., Wu C.Y., Rezaeian A.H., Chan C.H., Li J.M., Wang J., Gao Y., Han F., Jeong Y.S., Yuan X., Khanna K.K., Jin J., Zeng Y.X., Lin H.K. Skp2 E3 ligase integrates ATM activation and homologous recombination repair by ubiquitinating NBS1. Mol. Cell 2012, 46:351-361.
64. Quennet V., Beucher A., Barton O., Takeda S., Lobrich M. CtIP and MRN promote non-homologous end-joining of etoposide-induced DNA double-strand breaks in G1. Nucleic Acids Res. 2011, 39:2144-2152.
65. Goodarzi A.A., Noon A.T., Deckbar D., Ziv Y., Shiloh Y., Lobrich M., Jeggo P.A. ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin. Mol. Cell 2008, 31:167-177.
66. Yuan Z., Zhang X., Sengupta N., Lane W.S., Seto E. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol. Cell 2007, 27:149-162.
67. Shen H., Chen Z., Ding X., Qi X., Cen J., Wang Y., Yao L., Chen Y. BMI1 reprogrammes histone acetylation and enhances c-fos pathway via directly binding to Zmym3 in malignant myeloid progression. J. Cell. Mol. Med 2014, 18(6):1004-1017.
68. Iyengar S., Farnham P.J. KAP1 protein: an enigmatic master regulator of the genome. J. Biol. Chem. 2011, 286:26267-26276.
69. Ziv Y., Bielopolski D., Galanty Y., Lukas C., Taya Y., Schultz D.C., Lukas J., Bekker-Jensen S., Bartek J., Shiloh Y. Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway. Nat. Cell Biol. 2006, 8:870-876.
70. Waseem A., Ali M., Odell E.W., Fortune F., Teh M.T. Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncol. 2010, 46:536-542.
71. Zou L., Elledge S.J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 2003, 300:1542-1548.
72. Yang X.H., Zou L. Recruitment of ATR-ATRIP, Rad17, and 9-1-1 complexes to DNA damage. Methods Enzymol. 2006, 409:118-131.
73. Barsotti A.M., Prives C. Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene 2009, 28:4295-4305.
74. de Olano N., Koo C.Y., Monteiro L.J., Pinto P.H., Gomes A.R., Aligue R., Lam E.W. The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment. Mol. Cancer Res. 2012, 10:1189-1202.
75. Myatt S.S., Kongsema M., Man C.W., Kelly D.J., Gomes A.R., Khongkow P., Karunarathna U., Zona S., Langer J.K., Dunsby C.W., Coombes R.C., French P.M., Brosens J.J., Lam E.W. SUMOylation inhibits FOXM1 activity and delays mitotic transition. Oncogene 2014, 33:4316-4329.
76. Mowla S.N., Lam E.W., Jat P.S. Cellular senescence and aging: the role of B-MYB. Aging Cell 2014, 13(5):773-779.
77. Down C.F., Millour J., Lam E.W., Watson R.J. Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb. Biochim. Biophys. Acta 2012, 1819:855-862.
78. Sadasivam S., Duan S., DeCaprio J.A. The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. Genes Dev. 2012, 26:474-489.
79. Grant G.D., Brooks L., Zhang X., Mahoney J.M., Martyanov V., Wood T.A., Sherlock G., Cheng C., Whitfield M.L. Identification of cell cycle-regulated genes periodically expressed in U2OS cells and their regulation by FOXM1 and E2F transcription factors. Mol. Biol. Cell 2013, 24:3634-3650.
80. Tian T., Li J., Li B., Wang Y., Li M., Ma D., Wang X. Genistein exhibits anti-cancer effects via down-regulating FoxM1 in H446 small-cell lung cancer cells. Tumour Biol. 2014, 35:4137-4145.
81. Li S.K., Smith D.K., Leung W.Y., Cheung A.M., Lam E.W., Dimri G.P., Yao K.M. FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression. J. Biol. Chem. 2008, 283:16545-16553.
82. Kwok J.M., Myatt S.S., Marson C.M., Coombes R.C., Constantinidou D., Lam E.W. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol. Cancer Ther. 2008, 7:2022-2032.
83. Radhakrishnan S.K., Bhat U.G., Hughes D.E., Wang I.C., Costa R.H., Gartel A.L. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 2006, 66:9731-9735.
84. Hegde N.S., Sanders D.A., Rodriguez R., Balasubramanian S. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat. Chem. 2011, 3:725-731.
85. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.